Influence of relative humidity on the interaction between different aryl propionic acid derivatives and poly(vinylpyrrolydone) K30: Evaluation of the effect on drug bioavailability

International Journal of Pharmaceutics

Volumn 398, Issue 1-2, 2010, Pages 61-72

  Malaj, Ledjan ^a,b   Censi, Roberta ^b   Mozzicafreddo, Matteo ^b   Pellegrino, Luca ^c   Angeletti, Mauro ^b   Gobetto, Roberto ^c   Di Martino, Piera ^b  

^a UNIVERSITY OF TIRANA   (Albania)

^b UNIVERSITY OF CAMERINO   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Interaction; Physical characterization; Preformulation; Solid dispersion; Water in solids

Indexed keywords

FENBUFEN; FLURBIPROFEN; IBUPROFEN; KETOPROFEN; NAPROXEN; POVIDONE; PROPIONIC ACID DERIVATIVE;

ARTICLE; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; HUMIDITY; HYDROGEN BOND; MOLECULAR DOCKING; PHYSICAL CHEMISTRY; PREFORMULATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; THERMAL ANALYSIS; WATER CONTENT; WATER TRANSPORT; X RAY POWDER DIFFRACTION;

BIOLOGICAL AVAILABILITY; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HUMIDITY; POVIDONE; PROPIONIC ACIDS; X-RAY DIFFRACTION;

EID: 77956232262     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.07.024     Document Type: Article

References (37)

1. Ahlneck C., Zografi G. The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state. Int. J. Pharm. 1990, 62:87-95.
2. Andronis V., Yoshioka M., Zografi G. Effects of sorbed water on the crystallization of indomethacin from the amorphous state. J. Pharm. Sci. 1997, 86:346-351.
3. Banakar U.V. Pharmaceutical Dissolution Testing 1992, 55-105. Marcel Dekker, New York. J. Swarbrick (Ed.).
4. Bogdanova S., Pajeva I., Nikolova P., Tsakovska I., Müller B. Interactions of poly(vinylpyrrolidone) with ibuprofen and naproxen: experimental and modeling studies. Pharm. Res. 2005, 5:806-815.
5. Bohm H.J. Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs. J. Comput. Aided Mol. Des. 1998, 12:309-323.
6. Chiou W.L., Riegelman S. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 1971, 60:1281-1302.
7. Crowley K.J., Zografi G. Water vapour absorption into amorphous hydrophobic drug/poly(vinylpyrrolidone) dispersions. J. Pharm. Sci. 2002, 90:2150-2165.
8. Dauber-Osguthorpe P., Roberts V.A., Osguthorpe D.J., Wolff J., Genest M., Hagler A.T. Structure and energetics of ligand binding to proteins: E. coli dihydrofolate reductase-trimethoprim, a drug-receptor system. Proteins: Struct. Funct. Genet. 1988, 4:31-47.
9. Di Martino P., Joiris E., Gobetto R., Masic A., Palmieri G.F., Martelli S. Ketoprofen-poly(vinylpyrrolidone) physical interaction. J. Cryst. Growth 2004, 265:302-308.
10. Fitzpatrick S., McCabe J.F., Petts C.R., Booth S.W. Effect of moisture on polyvinylpyrrolidone in accelerated stability testing. Int. J. Pharm. 2002, 246:143-151.
11. Gashi Z., Censi R., Malaj L., Gobetto R., Mozzicafreddo M., Angeletti M., Masic A., Di Martino P. Differences in the interaction between aryl proprionic acid derivatives and poly(vinylpyrrolidone) K30: a multi-methodological approach. J. Pharm. Sci. 2009, 98:4216-4228.
12. Gordon M., Taylor J.S. Ideal copolymers and the second-order transitions of synthetic rubbers. I. Noncrystalline copolymers. J. Appl. Chem. 1952, 2:493-500.
13. Hamaura T., Newton J.M. Interaction between water and poly(vinylpyrrolidone) containing polyethylene glycol. J. Pharm. Sci. 1999, 88:1228-1232.
14. Jørgensen A.C., Torstenson A.S. Humid storage conditions increase the dissolution rate of diazepam from solid dispersions prepared by melt agglomeration. Pharm. Dev. Technol. 2008, 13:187-195.
15. Khougaz K., Clas S.D. Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone) polymers. J. Pharm. Sci. 2000, 89:1325-1334.
16. Kontny M.J., Zografi G. Sorption of water by solids. Physical Characterization of Pharmaceutical Solids 1995, 387-418. Marcel Dekker, New York. H.G. Brittain (Ed.).
17. Law D., Krill S.L., Schmitt E.A., Fort J.J., Qiu Y., Wang W., Porter W.R. Physico-chemical considerations in the preparation of amorphous ritonavir-poly(ethylene glycol) 8000 solid dispersions. J. Pharm. Sci. 2001, 90:1015-1025.
18. Leuner C., Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 2000, 50:47-60.
19. Löbenberg R., Amidon G.L. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 2000, 50:3-12.
20. Nair R., Nyamweya N., Gönen S., Martínez-Miranda L.G., Hoag S.W. Influence of various drugs on the glass transition temperature of poly(vinylpyrrolidone): a thermodynamic and spectroscopic investigation. Int. J. Pharm. 2001, 225:83-96.
21. Oksanen C.A., Zografi G. The relationship between the glass transition temperature and water vapour absorption by poly(vinylpyrrolidone). Pharm. Res. 2000, 7:654-657.
22. Schmitt E., Davis C.W., Long S.T. Moisture-dependent crystallization of amorphous lamotrigine mesylate. J. Pharm. Sci. 1996, 85:1215-1219.
23. Schneider H.A. Glass transition behaviour of compatible polymer blends. Polymer 1989, 30:771-779.
24. Sekikawa H., Nakano M., Arita T. Inhibitory effect of polyvinylpyrrolidone on the crystallization of drugs. Chem. Pharm. Bull. 1978, 26:118-126.
25. Sekizaki H., Danjo K., Eguchi H., Yonezawa Y., Sunada H., Otsuka A. Solid-state interaction of ibuprofen with polyvinylpyrrolidone. Chem. Pharm. Bull. 1995, 43:988-993.
26. Serajuddin A.T.M. Solid dispersions of poorly-water soluble drugs: early promises, subsequent problems and recent breakthroughs. J. Pharm. Sci. 1999, 88:1058-1066.
27. Shamblin S.L., Zografi G. The effects of absorbed water on the properties of amorphous mixtures containing sucrose. Pharm. Res. 1999, 16:1119-1124.
28. Simha R., Bayer R.F. General relation involving the glass temperature and coefficient of expansion of polymers. J. Chem. Phys. 1962, 37:1003-1007.
29. Simonelli A.P., Mehta S.C., Higuchi W.I. Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone. J. Pharm. Sci. 1970, 59:633-638.
30. Taylor L.S., Langkilde F.W., Zografi G. Fourier transform Raman spectroscopy study of the interaction of water vapor with amorphous polymers. J. Pharm. Sci. 2001, 90:888-901.
31. Taylor L.S., Zografi G. Spectroscopic characterization of intercations between PVP and indomethacin in amorphous molecular dispersions. Pharm. Res. 1997, 14:1691-1698.
32. Urbanetz N.A., Lippold B.C. Solid dispersions of nimodipine and polyethylene glycol 2000: dissolution properties and physico-chemical characterization. Eur. J. Pharm. Biopharm. 2005, 59:107-118.
33. Van den Mooter G., Wuyts M., Blaton N., Busson R., Grobet P., Augustijns P., Kinget R. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur. J. Pharm. Sci. 2001, 12:261-269.
34. Van Drooge D.J., Hinrichs W.L.J., Visser M.R., Frijlink H.W. Characterization of the molecular distribution of the drugs in glassy solid dispersions at the nano-meter scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques. Int. J. Pharm. 2006, 310:220-229.
35. Vasconcelos T., Sarmento B., Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today 2007, 12:1068-1075.
36. Yoshioka M., Hancock B.C., Zografi G.J. Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J. Pharm. Sci. 1995, 84:983-986.
37. Zografi G. States of water associated with solids. Drug Dev. Ind. Pharm. 1988, 14:1905-1926.